Crinetics Pharmaceuticals Inc
NASDAQ:CRNX
Crinetics Pharmaceuticals Inc
NASDAQ:CRNX
Price:
50.49 USD
2.25%
Market Closed
Updated:
May 15, 2024
Section:
Relative Value
The Relative Value of one
CRNX
stock under the Base Case scenario is
10.58
USD.
Compared to the current market price of 50.49 USD,
Crinetics Pharmaceuticals Inc
is
Overvalued by 79%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CRNX
Relative Value
Base Case
10.58
USD
Overvaluation 79%
Valuation Multiples
Multiples Across Competitors
CRNX Competitors Multiples
Crinetics Pharmaceuticals Inc Competitors
Crinetics Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Crinetics Pharmaceuticals Inc
NASDAQ:CRNX
|
4B USD | 2 002.7 | -16.8 | -12.4 | -12.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
289.1B USD | 5.3 | 60 | 13 | 19.8 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
171.1B USD | 5.8 | 45.5 | 19.1 | 31.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.7B USD | 11.4 | 31.1 | 25.2 | 26.4 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.8B USD | 8.2 | 27.9 | 22.6 | 25.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
136.7B AUD | 6.4 | 36.6 | 22.1 | 27.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
83.7B USD | 3 | 172.9 | 7 | 9.1 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
49.3B USD | 9.6 | -8.3 | -9.1 | -8.1 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
34.2B USD | 3.5 | 29.3 | 14.9 | 18.6 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.6T KRW | 18.2 | 73.8 | 45.2 | 62.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
